Skip to content
healthcare.dev

LYTGOBI

NDC 64842-0120, FUTIBATINIB, tablet, from TAIHO PHARMACEUTICAL CO., LTD..

Product NDC
64842-0120
Status
Listed
Labeler
TAIHO PHARMACEUTICAL CO., LTD.
Dosage form
TABLET
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
NDA
Application
NDA214801
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/64842-0120 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • FUTIBATINIB4 mg/1

Pharmacologic classes

Breast Cancer Resistance Protein Inhibitors [MoA]; Fibroblast Growth Factor Receptor Inhibitors [MoA]; Kinase Inhibitor [EPC]; P-Glycoprotein Inhibitors [MoA]

Package NDCNDC-11Package
64842-0120-4648420120041 BLISTER PACK in 1 CARTON (64842-0120-4) / 21 TABLET in 1 BLISTER PACK
64842-0120-5648420120051 BLISTER PACK in 1 CARTON (64842-0120-5) / 28 TABLET in 1 BLISTER PACK
64842-0120-6648420120061 BLISTER PACK in 1 CARTON (64842-0120-6) / 35 TABLET in 1 BLISTER PACK

Linked data

RxNorm, label and prices

Use it

Look up 64842-0120 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/64842-0120 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 64842-0120. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.